Examination of Questionnaire Items regarding Diabetic Peripheral Neuropathy in Epalrestat-treated Patients and Their Usefulness in the Treatment of This Disorder―Influence on Treatment Course

• Published in: YAKUGAKU ZASSHI (Journal of the Pharmaceutical Society of Japan) Vol. 129; no. 10; pp. 1239 - 1247
• Main Authors: Atsuo ITOa, b, Reiko ISHII-NOZAWAb, Chikao IBUKIc, Hirotsugu ATARASHId, Hirokuni KATAOKAa, Koichi TAKEUCHIb
• Format: Journal Article
• Language: Japanese
• Published: Pharmaceutical Society of Japan 2009
• ISSN: 0031-6903

Epalrestat (Kinedak(R)) is an aldose reductase inhibitor (ARI) for diabetic peripheral neuropathy. In 41 diabetics, we conducted a questionnaire survey to evaluate symptoms of peripheral neuropathy and select appropriate drug therapy. We investigated 27 patients who participated in the first and second questionnaire surveys. We reviewed questionnaire items, and examined the correlation between the therapeutic effects and responses to the questionnaire. Concerning the usefulness of the questionnaire items, some questions were correlated with the effects. Treatment was effective for somatic neuropathy, but not for autonomic neuropathy. The questionnaire regarding diabetic peripheral neuropathy was useful for somatic neuropathy screening, but it was difficult to detect autonomic neuropathy. [INTRODUCTION]The pathogenesis of diabetic peripheral neuropathy may involve the neurocytic accumulation of sorbitol, in which the activity of a rate-limiting enzyme involved in polyol metabolism, aldose reductase (AR), is enhanced in the presence of hyperglycemia1).